SubsidieMeestersTruly portable MRI for extremity and brain imaging anywhere & everywhere
The NextMRI project aims to develop portable low-field MRI systems for accessible point-of-care imaging, enhancing diagnostic capabilities and usability for underserved populations globally.
Projectdetails
Introduction
Mobile medical imaging devices are invaluable for clinical diagnostic purposes both inside and outside healthcare institutions. Unfortunately, Magnetic Resonance Imaging (MRI), the gold standard for numerous neurological and musculoskeletal conditions, is not readily portable.
Current Challenges
Recently, low-field MRI companies have demonstrated the first decisive steps towards portability within medical facilities and vehicles. However, the scanners' weight and dimensions are still incompatible with more demanding use cases such as:
- Remote and developing regions
- Sports facilities and events
- Medical and military camps
- Home healthcare
Recent Developments
Within the Histo-MRI and PR Scanner projects, we have recently demonstrated in vivo images taken with a light, small footprint, low-field extremity MRI scanner outside the controlled settings provided by medical facilities. This includes:
- The first-ever MRI images obtained at a patient's home
- MRI images captured in open air connected to a gasoline generator
This has opened a path towards highly accessible MRI under circumstances previously unrealistic.
Project Goals
In this project, we will take the necessary technical, industrial, and entrepreneurial steps to tackle the massive deployment of low-field portable systems for point-of-care and bedside imaging in various settings, including:
- Clinics large and small
- Home and hospice care
- Rural areas
- Sports facilities and events
- Field hospitals
- NGO and military camps
Our aim is to make MRI available to a large fraction of the world population with no or insufficient access.
Objectives
To advance towards this highly ambitious goal, the objectives of the NextMRI project include:
- Expanding the current technology to both extremity and brain imaging
- Improving the diagnostic capabilities with machine learning
- Improving the portability and usability to meet end-user needs
- Optimizing production costs
- Gathering medical evidence of the technology performance with clinical trials
- Developing a sustainable business case and model towards commercialization
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.494.415 |
| Totale projectbegroting | € 2.494.415 |
Tijdlijn
| Startdatum | 1-10-2023 |
| Einddatum | 30-9-2026 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICASpenvoerder
- PHYSIO MRI TECH SL
- ACADEMISCH ZIEKENHUIS LEIDEN
- FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA
- BERGMAN GERMANY HOLDCO GMBH
Land(en)
Vergelijkbare projecten binnen EIC Transition
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Targeting cardiac fibrosis with next generation RNA therapeuticsFIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness. | EIC Transition | € 2.499.482 | 2022 | Details |
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationSThe NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring. | EIC Transition | € 2.497.750 | 2022 | Details |
Predictive REagent-Antibody Replacement Technology stage 2-TranslationPRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment. | EIC Transition | € 800.000 | 2022 | Details |
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stageDeveloping a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships. | EIC Transition | € 2.499.810 | 2022 | Details |
Targeting cardiac fibrosis with next generation RNA therapeutics
FIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness.
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationS
The NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring.
Predictive REagent-Antibody Replacement Technology stage 2-Translation
PRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment.
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stage
Developing a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
MAGNIFICO-Pre-commercialization of multifunctional targeted MRI-contrast enhancing agents for brain researchThis project aims to enhance MRI's capabilities for brain disease research by developing targeted fluorescent contrast agents and engineering cells for improved in vivo imaging. | ERC POC | € 150.000 | 2022 | Details |
Enabling Unobtrusive Real-World Monitoring of Brain-Networks with Wearable Neurotechnology and Multimodal Machine LearningThe INTEGRAL project aims to develop a hybrid wearable platform combining HD-DOT and EEG for continuous brain network imaging in everyday environments, enhancing neurotechnology research and applications. | ERC STG | € 1.654.850 | 2025 | Details |
Accessible MRIThe AMRI project by CHIPIRON aims to develop an affordable, compact MRI scanner using ultra-low magnetic fields to enhance accessibility and diagnostic capabilities in underserved regions. | EIC Accelerator | € 2.499.999 | 2024 | Details |
d MRI force sensorsDit project onderzoekt welke trainingsapparatuur patiënten thuis kunnen gebruiken voor prehabilitatie, door de relatie tussen fysieke fitheid en gezondheidsparameters te analyseren met MRI-scanners. | MIT Haalbaarheid | € 19.720 | 2023 | Details |
MAGNIFICO-Pre-commercialization of multifunctional targeted MRI-contrast enhancing agents for brain research
This project aims to enhance MRI's capabilities for brain disease research by developing targeted fluorescent contrast agents and engineering cells for improved in vivo imaging.
Enabling Unobtrusive Real-World Monitoring of Brain-Networks with Wearable Neurotechnology and Multimodal Machine Learning
The INTEGRAL project aims to develop a hybrid wearable platform combining HD-DOT and EEG for continuous brain network imaging in everyday environments, enhancing neurotechnology research and applications.
Accessible MRI
The AMRI project by CHIPIRON aims to develop an affordable, compact MRI scanner using ultra-low magnetic fields to enhance accessibility and diagnostic capabilities in underserved regions.
d MRI force sensors
Dit project onderzoekt welke trainingsapparatuur patiënten thuis kunnen gebruiken voor prehabilitatie, door de relatie tussen fysieke fitheid en gezondheidsparameters te analyseren met MRI-scanners.